Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BASi Announces First-of-Its-Kind Pivotal Study with Data Sciences International



  BASi Announces First-of-Its-Kind Pivotal Study with Data Sciences
  International

Business Wire

WEST LAFAYETTE, Ind. -- December 07, 2012

BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) today announced that it is
collaborating with Data Sciences International (DSI), a biomedical research
company focused on preclinical systems physiology and pharmacology, to conduct
a first-of-its-kind study combining BASi’s Culex^®-L automated sampling system
with DSI’s newest large animal telemetry technology, PhysioTel^™ Digital.

In this pivotal study, BASi’s Culex^®-L automated in vivo sampling system will
simultaneously collect biological samples at pre-programmed intervals while
DSI telemetry devices will collect heart rate, blood pressure and other
cardiovascular information. Previously, gathering all of these types of data
required two separate experiments and only discontinuous data collection was
possible.

“By combining Culex^® with telemetry, the automated blood sampling and
telemetry (ABST) system will reduce costs, the number of test subjects,
subject stress levels, and deliver better data, which will lead to better
decisions,” said Jacqueline M. Lemke, interim president & CEO and CFO of BASi.
“This study lays the groundwork for additional safety pharmacology studies
that further complement BASi’s long-established and well-respected CRO
services expertise.”

“We’re responding to customers’ requests for more and better pharmacokinetic
data. We know how important these data are for early decision-making in the
drug discovery process. Combining DSI’s telemetry with BASi’s automation is a
natural fit,” said Dr. Dusty Sarazan, Vice President and CSO of DSI.

About Data Sciences International

DSI, with headquarters in St. Paul, Minnesota, is the recognized global leader
in physiologic monitoring, offering telemetry, instrumentation, software and
services that help advance science. DSI’s solutions are tailored to the unique
research needs of customers in industries including pharmaceuticals, academia,
contract research, biological and chemical defense, medical devices,
government and biotechnology. Visit www.datasci.com for more about DSI.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
about BASi.

This release contains forward-looking statements that are subject to risks and
 uncertainties including, but not limited to, risks and uncertainties related
    to changes in the market and demand for our products and services, the
    development, marketing and sales of products and services, changes in
 technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
                             Exchange Commission.

Contact:

Company Contact:
Bioanalytical Systems, Inc.
Jacqueline Lemke
Interim President & CEO and CFO
Phone: 765.497.5829
jlemke@BASinc.com
or
Agency Contact:
Berkman Associates
Neil Berkman
Phone: 310.477.3118
info@berkmanassociates.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement